The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Johnson & Johnson Innovative Medicine, said in a statement. "Spravato is now available as a standalone treatment, meaning ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

(RTTNews) - Johnson & Johnson (JNJ), Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with ...

Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this ...